EUCRU

Eucrates Biomedical Acquisition Corp.

Price

return (12m)

p/e

18.08

p/bv

-11.34

DIVIDEND YIELD

0.00%

EUCRU price

Eucrates Biomedical

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment EUCRU

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals EUCRU

Valuation

P/E

18.08

Sector -139.65

Industry 10.95

P/BV

-11.34

Sector -10.05

Industry 1.68

P/Revenue (PSR)

Sector -11.25

Industry 1.62

EV/EBITDA

Sector -1,043.99

Industry 10.56

EV/EBIT

Sector -3,664,431,136.53

Industry 9.05

P/EBITDA

38.50

Sector -110.70

Industry 7.85

P/EBIT

38.50

Sector -127.46

Industry 5.61

P/Total Assets

3.38

Sector 0.14

Industry 0.49

P/Net Current Assets

Sector -10.46

Industry -0.66

P/Working Capital

Sector -

Industry -3.49

EPS

0.55

Sector -9,547.75

Industry 13.05

BVPS

-0.88

Sector -8,481.76

Industry 68.27

Efficiency

Gross Margin

0.00%

Sector 0.92%

Industry 20.69%

EBITDA Margin

Sector -292.19%

Industry 15.51%

EBIT Margin

0.00%

Sector -7.22%

Industry 6.87%

Net Profit Margins

0.00%

Sector -2.47%

Industry 14.88%

Asset Turnover

Sector 0.01

Industry 0.08

Profitability

ROE

-62.71%

Sector -1,328.29%

Industry 17.28%

ROA

18.67%

Sector -8.22%

Industry 4.89%

ROIC

Sector -12.38%

Industry 2.05%

Dividends

Dividend yield

0.00%

Sector 0.26%

Industry 1.91%

Payout

0.00%

Sector 5.25%

Industry 18.09%

Debt

Current Ratio

Sector -

Industry 0.86

Net Debt / EBITDA

Sector -159.63

Industry -15.82

Net Debt / EBIT

Sector -3,461,725,776.83

Industry -22.01

Net Debt / Equity

Sector -0.82

Industry -0.55

Gross Debt / Equity

Sector -0.24

Industry 0.04

Equity/Assets

-0.30

Sector -0.03

Industry 0.27

Liabilities/Assets

-0.30

Sector 0.36

Industry 0.73

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-13.35%

Sector -

Industry -

Fundamentals EUCRU

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
EUCRU Eucrates Biomedical Acquisition Corp.	$0.00	-	0.00%	18.08	-11.34	-62.71%	0.00%
PSEC Prospect Capital Corporation	$1.54	-31.93%	31.06%	5.26	0.28	5.25%	30.79%
GOLD Gold.com, Inc.	$38.81	47.33%	4.52%	13.18	1.24	9.40%	0.32%
PFLT PennantPark Floating Rate Capital Ltd.	$6.33	-14.77%	17.47%	13.03	0.64	4.94%	62.69%
CSWC Capital Southwest Corporation	$22.53	26.95%	11.22%	12.55	1.31	10.46%	72.73%
STT State Street Corporation	$165.82	52.43%	2.07%	12.79	1.61	12.61%	15.54%
OCSL Oaktree Specialty Lending Corporation	$11.35	-1.82%	12.57%	24.38	0.74	3.05%	15.75%
PNNT PennantPark Investment Corporation	$2.96	-43.28%	31.12%	19.88	0.47	2.37%	16.48%
GBDC Golub Capital BDC Inc.	$12.01	-4.08%	11.31%	18.51	0.86	4.64%	48.49%
MAGS Magal Security Systems Ltd.	$72.55	14.43%	1.36%	176.87	21.10	11.93%	14.66%
RPRX Royalty Pharma PLC	$60.11	65.58%	1.53%	33.34	2.77	8.30%	32.02%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

EUCRU - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Eucrates Biomedical

Eucrates Biomedical Acquisition Corp.

Average Investor10 user rating

4.0 (0 people)

United States

6 years

Founded: 2020

2020

Time since IPO - 6 years

-

Employees

Eucrates Biomedical Acquisition Corp. (United States) is listed on the Nasdaq and has a market capitalization of $42.14 million, with shareholders equity totaling $-3.72 million.

The Company is listed on the [MARKET_NAME]

Over the past 12 months, Eucrates Biomedical Acquisition Corp. reported $- in revenue, generating net income of $2.33 million.

Key financial metrics include a P/E ratio of 18.08, a price-to-book (P/B) ratio of -11.34, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker EUCRU.

Market cap

$42.14 million

Net worth

$-3.72 million

$-3,717,596.00

Assets

$12.49 million

$12,485,358.00

Total Shares Outstanding

4.21 million

4,206,000

Average Daily Trading Volume

$596.22

Sector

Financial

Industry

Auxiliary Activities of Financial Services

EUCRU

EUCRU revenue and profits

Financial Results EUCRU

DRAG THE FRAME TO SEE MORE DATA

EUCRU cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BRK-A - Berkshire Hathaway

$795,800.00 7,80% (12M)

P/E

13.28

0.00%

ROE

11.45%

P/BV

1.52

BRK-B - Berkshire Hathaway

$530.81 7,80% (12M)

P/E

13.28

0.00%

ROE

11.46%

P/BV

1.52

ING - ING Group

$32.94 43,14% (12M)

P/E

3.26

3.98%

ROE

23.39%

P/BV

0.76

JPM - JPMorgan

$336.12 15,71% (12M)

P/E

14.02

1.77%

ROE

17.37%

P/BV

2.44

LYG - Lloyds Banking Group

$5.42 25,50% (12M)

P/E

3.45

3.97%

ROE

12.34%

P/BV

0.43

DB - Deutsche Bank

$31.82 --2,72% (12M)

P/E

4.65

2.65%

ROE

7.85%

P/BV

0.36

BCS - Barclays

$22.20 17,25% (12M)

P/E

7.33

2.67%

ROE

5.81%

P/BV

0.43

SNEX - StoneX Group

$56.92 27,73% (12M)

P/E

12.72

0.00%

ROE

18.53%

P/BV

2.36